B
Benjamin M. Parsons
Researcher at Gundersen Health System
Publications - 32
Citations - 2029
Benjamin M. Parsons is an academic researcher from Gundersen Health System. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 9, co-authored 26 publications receiving 1210 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Andrea L. Webber,Scot Ebbinghaus,Junshui Ma,Abby B. Siegel,Ann-Lii Cheng,Masatoshi Kudo,Angela Tatiana Alistar,Jamil Asselah,Jean-Frédéric Blanc,Ivan Borbath,Timothy Cannon,Ki Chung,Allen Lee Cohn,David Cosgrove,Nevena Damjanov,Mukul Gupta,Yoshivasu Karino,Mark Karwal,Andreas Kaubisch,Robin Kate Kelley,Jena-Luc Van Laethem,Timothy Larson,James Lee,Daneng Li,Atisha Manhas,Gulam Abbas Manji,Kazushi Numata,Benjamin M. Parsons,Andrew Scott Paulson,Carmine Pinto,Robert A. Ramirez,Suresh Ratnam,Magnus Rizell,Olivier Rosmorduc,Yvonne Sada,Yutaka Sasaki,Per I Stal,Simone I. Strasser,Joerg Trojan,Gina M. Vaccaro,Hans Van Vlierberghe,Alan Weiss,Karl-Heinz Weiss,Tatsuya Yamashita +58 more
TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.
Journal ArticleDOI
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji Kumar,Susanna Jacobus,Adam D. Cohen,Matthias Weiss,Natalie S. Callander,Avina K. Singh,Terri L. Parker,Alexander R. Menter,Xuezhong Yang,Benjamin M. Parsons,Pankaj Kumar,Prashant Kapoor,Aaron S. Rosenberg,Jeffrey A. Zonder,Edward A. Faber,Sagar Lonial,Kenneth C. Anderson,Paul G. Richardson,Robert Z. Orlowski,Lynne I. Wagner,S. Vincent Rajkumar +20 more
TL;DR: This multicentre, open-label, phase 3, randomised controlled trial aimed to assess whether the KRd regimen is superior to the VRd regimen in the treatment of newly diagnosed multiple myeloma in patients who were not being considered for immediate autologous stem-cell transplantation (ASCT).
Journal ArticleDOI
Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database.
Devalkumar J. Rajyaguru,Chaithanya Bhaskar,Andrew J. Borgert,Angela L. Smith,Benjamin M. Parsons +4 more
TL;DR: On multivariate analysis advanced age, advanced stage and having Medicaid or Medicare insurance predicted worse OS, whereas female gender and use of radiation therapy predicted better OS.
Journal ArticleDOI
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.
Shaji Kumar,Susanna Jacobus,Adam D. Cohen,Matthias Weiss,Natalie S. Callander,Avina A. Singh,Terri L. Parker,Alex R. Menter,Xuezhong Yang,Benjamin M. Parsons,Pankaj Kumar,Prashant Kapoor,Aaron S. Rosenberg,Jeffrey A. Zonder,Edward A. Faber,Sagar Lonial,Paul G. Richardson,Robert Z. Orlowski,Lynne I. Wagner,S. Vincent Rajkumar +19 more
TL;DR: In this randomized phase 3 trial, KRd did not improve PFS compared with VRd in NDMM and VRd remains the standard triplet induction regimen in standard and intermediate risk NDMM, and a suitable backbone for 4 drug combinations.
Journal ArticleDOI
Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board
Mark E. Burkard,Dustin A. Deming,Benjamin M. Parsons,Paraic A. Kenny,Marissa Schuh,Ticiana Leal,Nataliya Volodymyrivna Uboha,Joshua M. Lang,Michael A. Thompson,Ruth Warren,Jordan Bauman,Mary S Mably,Jennifer Laffin,Catherine Randall Paschal,Angela M. Lager,Kristy Lee,Kristina A. Matkowskyj,Darya Buehler,William M. Rehrauer,Jill M. Kolesar +19 more
TL;DR: The Precision Medicine Molecular Tumor Board provides a model for a regional molecular tumor board with clinical utility and highlights the need for outcome registries and improved access to clinical trials to pragmatically implement precision oncology.